Fundraising FoxOrbiMed — 2020 Investments
11 investments dated 2020 · listed companies and verified rows first · show all
Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.
BiotechHealthtech
Shelia Violette(Founder & Chief Scientific Officer)inMichael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)inLee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)inDavid Appugliese(Senior Vice President, Head of People)in
Co-investorsAtlas VentureAgent CapitalCU Healthcare Innovation FundOUP (Osage University Partners)Sanofi Ventures5AM Ventures+2 more
Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations.
BiotechHealthtechCambridge, US
Schuetz Thomas(Executive Officer, Director)inErrik Anderson(Executive Officer, Director)inThomas J. Schuetz(Executive Officer, Director)inVered Bisker-Leib(Executive Officer)inBarry Shin(Chief Financial Officer)inNeil Lerner(Senior Vice President, Chief Accounting Officer)in
Board seatStephen SquintoCarl Gordon· per SEC Form D
Co-investorsAlumni VenturesBioBritF-Prime CapitalForesite CapitalGV (Google Ventures)venBio Partners+3 more
Keros is a clinical-stage biopharmaceutical company developing product candidates that modulate signaling of the transforming growth factor-beta (TGF-β) family of proteins to treat disorders affecting blood cells and tissues such as bone, muscle, adipose and heart.
BiotechHealthtechLexington, US
Jasbir Seehra(Co-Founder, Chief Executive Officer and Director)in
BoardJulius Knowles(Director)Alon Lazarus(Director)inOhad Hammer(Director)Ran Nussbaum(Director)in
Board seatCarl Gordon· per SEC Form D
Co-investorsArkin CapitalForesite CapitalPontifax Venture Capital
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).
BiotechHealthtechSouth San Francisco, US
Samir Gharib(Executive Officer)inRICHARD KING(Executive Officer, Director)inJavier Szwarcberg(Chief Executive Officer)in
BoardSimpson Camilla(Director)Tiba Aynechi(Director)inBali Muralidhar(Director)in
Board seatDina Chaya· per SEC Form D · $53.6M raise · filed Feb 2023
Co-investorsAisling CapitalHealthCapRiverVest Venture PartnersAbingworthNorwest Venture PartnersNovo Holdings+1 more
Caris Life Sciences is a precision medicine company focused on molecular profiling and research to support cancer care and improve patient outcomes.
AI & Machine LearningBiotechDigital HealthHealthtechMedical Devices
David Dean Halbert(Chairman, Founder and CEO)
Co-investorsCoatue ManagementSilver Lake PartnersSixth StreetBraidwellMillennium Management
NeuroPace is a commercial-stage medical device company that develops the RNS System, a brain-responsive neurostimulation platform delivering real-time treatment at the seizure source for patients with drug-resistant epilepsy and other brain disorders.
Digital HealthHardwareHealthtechMedical DevicesMountain View, US
Rebecca Kuhn(Executive Officer)inFrank Fischer(Executive Officer, Director)Joel Becker(President, Chief Executive Officer and Director)inVince Burgess(Director)inRenee Ryan(Director)inRay Larkin(Director)
Co-investorsAccelmed PartnersNew Enterprise Associates (NEA)
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)inDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)
Co-investorsARCH Venture PartnersLifeforce CapitalDomain AssociatesEDB InvestmentsSection 32Frazier Life Sciences+10 more
GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases.
BiotechHealthtechMedical Devices
Jane Buckner(Scientific Co-founder (President, Benaroya Research Institute))Chandra Patel(Co-founder & SVP, Research and Development Operations)inDavid Rawlings(Scientific Co-founder and Senior Scientific Advisor)Andy Scharenberg(Scientific Co-founder, SAB Chair)Andy Walker(President and CEO)inTom Wickham(Chief Scientific Officer)
Co-investorsNovartis Venture FundJDRF T1D FundRA Capital
Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options.
BiotechHealthtech
Vlad Coric(Chairman & Chief Executive Officer)in
Co-investorsAisling CapitalAPERTURE Venture PartnersConnecticut InnovationsOUP (Osage University Partners)HBM Healthcare Investments
Koya Medical develops wearable compression therapy devices, including its Dayspring system, for treating conditions such as lymphedema, chronic venous insufficiency, and deep vein thrombosis.
HardwareHealthtechMedical DevicesOakland, US
Anand Doraiswamy(Executive Officer, Director)in
BoardJosh Baltzell(Director)inJan Garfinkle(Director)in
Co-investorsAphelion CapitalArboretum VenturesScientific Health DevelopmentZühlke VenturesAsahi Kasei Corporate VenturesCadence Healthcare Ventures
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)
Co-investorsAju IB InvestmentEcoR1 CapitalEvolution VC PartnersMPM BioImpactOUP (Osage University Partners)Pfizer Venture Investments+6 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.